Your session is about to expire
← Back to Search
PulsePoint for Opioid Overdose (PP-OD Trial)
N/A
Waitlist Available
Led By Jon Agley
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Layperson responders who are part of the PulsePoint system register with a local first responder agency using their smartphone. Anyone who is registered with a PulsePoint agency randomly selected for this project is included. Most layperson responders (eg, those who are not also off-duty first responders themselves) are only alerted to incidents in public spaces. No identifying information is collected from these users except the unique ID of the device
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether new procedures called PulsePoint-OD can effectively recruit first responder agencies and laypeople to distribute naloxone for opioid overdoses. They will compare the recruitment success between different groups
Who is the study for?
This trial is for layperson responders registered with a local first responder agency through the PulsePoint system. It includes those who are alerted to incidents in public spaces and does not collect personal information beyond device ID.
What is being tested?
The study tests if revised procedures on the PulsePoint app can improve recruitment of agencies and engagement with opioid overdose education and naloxone distribution, comparing customized push messages against standard ones.
What are the potential side effects?
Since this trial involves using an app for communication rather than medical interventions, there are no direct side effects like you'd expect from drugs or medical treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Certification of receiving OEND programming and naloxone carrying
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Customized layperson messaging (Arm 2)Experimental Treatment1 Intervention
Arm 2 will follow the same procedures that are described for arm 1 but will use separate messaging. Specifically, the push messages and landing page will contain additional, brief messages that specifically provide factual information that counteracts misperceptions about overdose and naloxone.
Group II: Standard layperson messaging (Arm 1)Active Control1 Intervention
Users randomized to arm 1 will receive standard monthly recruitment push messages. These push messages will differ from the certification messages because they will contain language intended to foster engagement with OEND services (eg, to get trained and carry naloxone) alongside the link to a landing page.
Group III: Control arm (Arm 3)Active Control1 Intervention
Arm 3 functions as the control arm and will not receive any monthly recruitment messaging or encouragement.
Find a Location
Who is running the clinical trial?
National Institute on Drug Abuse (NIDA)NIH
2,593 Previous Clinical Trials
3,323,696 Total Patients Enrolled
Indiana UniversityLead Sponsor
1,040 Previous Clinical Trials
1,215,064 Total Patients Enrolled
Jon AgleyPrincipal InvestigatorIndiana University